Theseus Pharmaceuticals is laying off 72% of its staff and exploring potential deals after its lead cancer drug revealed dose-limiting toxicities. The firm anticipates $5.5m in severance costs to be incurred this quarter. Despite the layoffs, Theseus still plans to further develop its pipeline, which could include treatments for lung cancer and other forms of gastrointestinal cancer.
Changes Are Likely on the Horizon for the Federal Healthcare Portfolio in Areas Including Cybersecurity and Regulatory Enforcement | Bond Schoeneck & King PLLC
Republican victories in recent US federal elections could affect how the healthcare sector will be regulated. Changes are expected as the focus shifts from a
